CDKN2A and neoplasm: For the CD7 xenograft, we did not observe any tumor growth response to both palbociclib and volasertib (p = 0.85 and p > 0.99, respectively), as well as for the CD39 xenograft without CDKN2A/2B deletion (p = 0.40 and 0.058, respectively).